For instance, vasoactive intestinal peptide (VIP) derivatives, such as IK312532, have demonstrated enhanced anti-inflammatory efficacy in asthma and chronic obstructive pulmonary disease (COPD) models when delivered via DPIs with reduced systemic side effects [15,16,17,18]. This evidence concerns the gene VIP and asthma.